Tools
GLP-1 titration calculator
GLP-1 medications are started low and stepped up over weeks to ease stomach side effects. This tool lays out that timeline: load a published label schedule, or enter a start dose, a step size, and a ceiling, and see the week-by-week plan and how long it takes to reach the top dose.
Reviewed 2026-08-29 · 7 sources
Load a published schedule
Or build a custom escalation
Semaglutide - Wegovy
From the FDA labelSteps
5
Top dose
2.4 mg
Weeks to top dose
16
Weeks charted
20
| Step | Weeks | Dose |
|---|---|---|
| 1 | Weeks 1-4 | 0.25 mg |
| 2 | Weeks 5-8 | 0.5 mg |
| 3 | Weeks 9-12 | 1 mg |
| 4 | Weeks 13-16 | 1.7 mg |
| 5 | Week 17 onward | 2.4 mg |
The last row is the maintenance dose, held from that week onward - the four-week window shown is just where escalation ends.
What the source says: The label says that if a patient does not tolerate a dose during escalation, the prescriber may delay the increase by 4 weeks.
Schedule math and a reference layout only. This lays out a timeline from the numbers entered or from a published schedule - it does not tell you what dose to take or how fast to escalate. GLP-1 medications are prescription drugs; dosing and escalation are decisions for you and a licensed prescriber, based on the actual product you hold.
How the schedule is built
A titration schedule is just arithmetic on a calendar. Start at the first dose, hold it for a set number of weeks, then step up by a fixed increment and hold again, repeating until you hit the maximum. The final step is clamped so it lands exactly on the max rather than overshooting. The label presets do not always use a fixed increment - semaglutide jumps 1 to 1.7 to 2.4 mg, for instance - so those render verbatim from the label rather than from a formula. This is schedule math and a reference layout, not a recommendation to take any dose.
Sources
- [1]WEGOVY (semaglutide) injection - DailyMed label, Novo Nordisk (Revised 4/2024)SemaglutideAdult weekly escalation: 0.25 mg (wk 1-4), 0.5 mg (wk 5-8), 1 mg (wk 9-12), 1.7 mg (wk 13-16), 2.4 mg maintenance (wk 17+); delay escalation 4 weeks if a dose is not tolerated
- [2]OZEMPIC (semaglutide) injection - DailyMed label, Novo Nordisk (Revised 5/2026)SemaglutideWeekly escalation: 0.25 mg start (4 wk), 0.5 mg, then 1 mg after >=4 wk, then 2 mg maximum after >=4 wk if additional glycemic control is needed
- [3]RYBELSUS (semaglutide) oral tablets - DailyMed label, Novo Nordisk (Revised 1/2026)SemaglutideOral daily escalation: 3 mg (days 1-30, not for glycemic control), 7 mg (days 31-60), 14 mg maximum (day 61+ if more control needed)
- [4]ZEPBOUND (tirzepatide) injection - DailyMed label, Eli Lilly (Revised 4/2026)TirzepatideStart 2.5 mg once weekly for 4 weeks, increase in 2.5 mg increments after at least 4 weeks up to a 15 mg maximum; maintenance 5/10/15 mg (weight) or 10/15 mg (OSA)
- [5]MOUNJARO (tirzepatide) injection - DailyMed label, Eli Lilly (Revised 4/2026)TirzepatideStart 2.5 mg once weekly, increase to 5 mg after 4 weeks, then 2.5 mg increments after >=4 weeks if needed; maximum 15 mg adults, 10 mg pediatric 10+
- [6]Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial - Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526. PMID 37366315.RetatrutideRandomized to retatrutide 1, 4 (initial 2 or 4 mg), 8 (initial 2 or 4 mg), or 12 mg (initial 2 mg) or placebo once weekly for 48 weeks; 12 mg produced -24.2% mean weight change vs -2.1% placebo
- [7]A Study of Retatrutide (LY3437943) in Participants With Obesity - ClinicalTrials.gov NCT04881760RetatrutideTrial record confirming the dose arms and starting-dose stratification (2 mg or 4 mg initial, escalating to 4, 8, or 12 mg target) for the Phase 2 obesity study
Pepteca is for education and information only. It does not provide medical advice, diagnosis, or treatment, and its calculators perform unit math only. Always verify with a licensed provider before starting, changing, or stopping any protocol. Many peptides are not approved for human use and may be regulated differently where you live.